CAG
NVAX icon

Crestwood Advisors Group’s Novavax NVAX Stock Holding History

Crestwood Advisors Group’s Portfolio NVAX Stock Details NVAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-2,245
Closed -$25K – 244
2019
Q1 		$25K Hold
2,245
– – ﹤0.01% 176
2018
Q4 		$83K Hold
2,245
– – 0.01% 157
2018
Q3 		$84K Hold
2,245
– – 0.01% 169
2018
Q2 		$61K Buy
2,245
+495
+28% +$16.7K ﹤0.01% 171
2018
Q1 		$74K Buy
+1,750
New +$70.3K 0.01% 174

Other funds holding NVAX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Crestwood Advisors Group's NVAX Position: Q2 2019 in Review

Crestwood Advisors Group sold out of Novavax (NVAX) in Q2 2019, closing a stake of 2,245 shares — an estimated $25K sold.

Crestwood Advisors Group first reported a position in NVAX in Q1 2018 and held it in 5 quarters. The position peaked at $84K in Q3 2018. 81 funds tracked by Wall St. Rank hold NVAX as of Q2 2019.

  • Crestwood Advisors Group reported no remaining Novavax position as of Q2 2019 after selling out during the quarter.
  • Crestwood Advisors Group sold 2,245 Novavax shares in Q2 2019, an estimated $25K.
  • Crestwood Advisors Group first reported a position in Novavax in Q1 2018 and held it in 5 quarters.
  • Crestwood Advisors Group's Novavax position peaked at $84K in Q3 2018.
  • 81 funds tracked by Wall St. Rank held Novavax as of Q2 2019.

Based on Crestwood Advisors Group's 13F filing for Q2 2019, filed 14 Aug 2019.